Developer docs
API playgroundTry for free, no card

Search company profiles

Cugene

Full company profile

uuid0009gy8

Namestring
Cugene
Legal namestring
Cugene, Inc.
Websiteurl
cugene.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Cugene, Inc. is a Boston-based clinical-stage biotechnology company founded in 2016, headquartered at 130 Turner Street, Suite 702, Waltham, MA. The company develops precision immunotherapies for cancer and autoimmune diseases using a biologics-based platform that combines engineered cytokines, bispecific antibodies, and a proprietary masking technology for tissue- or cell-selective targeting.

Cugene's pipeline is anchored by three technology platforms. CUG252 is a precision-engineered Treg-selective, long-acting IL-2 mutein designed to restore regulatory T cell functionality and suppress autoantibody production in autoimmune and inflammatory diseases, with an ongoing Phase 1b trial in Systemic Lupus Erythematosus (SLE) following FDA-cleared Phase 1a in healthy volunteers. In oncology, TILKine™ and VitoKine™ are TIL-targeting bispecific technologies engineered to selectively engage tumor-infiltrating lymphocytes, simultaneously blocking immune checkpoints and activating effector T cells through cis-signaling, with VitoKine additionally differentiated by a proprietary masking domain enabling tumor-specific activation. VitoKine-2 is a next-generation tumor-activable IL-2 therapeutic designed for monthly high-dose administration with an enlarged therapeutic window.

The business model is anchored on licensing and collaboration. In May 2022, Cugene entered into an exclusive worldwide license option agreement with AbbVie for CUG252 and other novel IL-2 muteins for autoimmune and inflammatory diseases, positioning the company to capture milestone and royalty economics while a major pharmaceutical partner handles global development and commercialization. The company is pre-revenue, with no disclosed product sales; revenue, if any, would flow from licensing milestones. The company markets through scientific conference presentations, peer-reviewed publications, and partnership announcements targeting investors and pharmaceutical partners rather than direct clinical end-users.

Short descriptiontext

Cugene is a Boston-based clinical-stage biotechnology company developing precision immunotherapies — including Treg-selective IL-2 and TIL-targeting bispecifics — for cancer and autoimmune diseases, with CUG252 in Phase 1b trials and a worldwide license option held by AbbVie.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, precision immunotherapy development, autoimmune disease therapeutics, oncology biologics, engineered cytokine therapy
Industry3 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals (Precision Immunotherapy)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Collaboration Agreements
TypeLicensing Royalties
Description

Pre-revenue clinical stage company generating income through exclusive licensing agreements with pharmaceutical partners. AbbVie collaboration provides potential milestone and royalty payments for CUG252 and other IL-2 muteins.

cugene.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cugene is a Boston-based clinical-stage biotechnology company developing a pipeline of precision immunotherapies for cancer and autoimmune diseases. Its portfolio centers on biologics-based therapeutics including CUG252 (a Treg-selective long-acting IL-2 mutein for autoimmune/inflammatory diseases), TILKine and VitoKine (TIL-targeting bispecific technologies for solid tumors), and VitoKine-2 (an advanced tumor-activable IL-2). These candidates are integrated with a proprietary masking technology that enables tissue- or cell-selective targeting to minimize systemic toxicity.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Complete tumor regressions observed in multiple cold and hot mouse models with efficacy superior to ICIs
+2 more records
Product overview1 text field

Cugene is a clinical-stage biotechnology company developing a pipeline of precision immunotherapies for cancer and autoimmune diseases. The company's product portfolio centers on its technology platform utilizing biologics-based therapeutics, including: CUG252 (a Treg-selective long-acting IL-2 for autoimmune diseases), TILKine™ and VitoKine™ (bispecific TIL-targeting technologies for oncology), and VitoKine-2 (an advanced tumor-activable IL-2 therapeutic). These products are integrated with proprietary masking technology and precision immuno-engineering to achieve tissue or cell-selective targeting with reduced systemic toxicity.

Product and service4 records
1CUG252
CategoryAutoimmune Biologics / Engineered Cytokine
Description

A precision engineered Treg-selective, long-acting IL-2 mutein that abolishes binding to effector cells and retains full agonist activity on IL-2α. It restores full Treg functionality, suppresses autoantibody production, and restores immune homeostasis for treating autoimmune and inflammatory diseases including Systemic Lupus Erythematosus (SLE).

2TILKine
CategoryOncology Biologics / Bispecific Antibody
Description

A TIL-targeting bispecific technology engineered to selectively engage tumor-reactive tumor-infiltrating lymphocytes (TILs) in the tumor environment. Through cis-signaling, it simultaneously blocks a key immune checkpoint and activates effector T cells, driving a potent and localized anti-tumor response. Aiming for first-line monotherapy for solid tumors.

3VitoKine
CategoryOncology Biologics / Masked Bispecific Cytokine
Description

A TIL-targeting bispecific technology uniquely differentiated by a proprietary masking domain that enables tumor-specific TIL activation, minimizing systemic immune activation. Together with TILKine, these technologies reinvigorate exhausted T cells and expand tumor-killing effector T cells for precise and profound tumor eradication.

4VitoKine-2
CategoryOncology Biologics / Masked IL-2 Therapeutic
Description

A precision-engineered tumor-activable IL-2 therapeutic designed to target tumor-infiltrating lymphocytes (TIL) in the tumor microenvironment. Uses unique masking technology to remain inert until activated, minimizing peripheral T cell activation and reducing systemic toxicities. Designed for monthly high-dose administration with an enlarged therapeutic window for both IO-responsive and unresponsive patients.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-16
Description

AbbVie and Cugene entered into an exclusive worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well as other novel IL-2 muteins for the potential treatment of autoimmune and inflammatory diseases. This collaboration positions Cugene's pipeline for global development and potential commercialization through a major pharmaceutical partner.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Roche has multiple engineered IL-2 and IL-15 programs (including collaborations with Squarex and others) targeting Treg expansion for autoimmune disease, and is the dominant broad incumbent in oncology biologics — a relevant comparable for both halves of Cugene's pipeline.

TypeDirect peer
Description

Nektar developed NKTR-358 (now rezpegaldesleukin, partnered with Eli Lilly), a Treg-selective IL-2 for autoimmune diseases — directly comparable to Cugene's CUG252 in mechanism, target selectivity approach, and indication strategy.

TypeBroad incumbent
Description

Sanofi is a global immunology leader (Dupixent franchise) actively pursuing Treg-focused and engineered cytokine programs for autoimmune indications, and a major oncology biologics player — overlapping with Cugene on both autoimmune and oncology axes.

TypeBroad incumbent
Description

Lilly acquired Dice Therapeutics and is partnered with Nektar on rezpegaldesleukin (Treg-selective IL-2), placing it as a large-cap incumbent competitor in the same autoimmune IL-2 space as CUG252, with materially greater development and commercial resources.

TypeDirect peer
Description

AnaptysBio is a clinical-stage biotech with proprietary antibody discovery and engineering platforms producing both wholly-owned and partnered antibodies for inflammation and immuno-oncology — comparable to Cugene in its biologics-platform-plus-pipeline model and therapeutic area focus.

TypeOthers
Description

AbbVie is Cugene's exclusive worldwide license option partner for CUG252 and other IL-2 muteins — a large-cap pharma incumbent in immunology and oncology and a critical strategic counterparty rather than a direct competitor.

TypeDirect peer
Description

Compass develops bispecific antibodies for oncology, with candidates designed to engage tumor-reactive immune cells — directly comparable to Cugene's TILKine/VitoKine bispecific strategy targeting tumor-infiltrating lymphocytes.

TypeDirect peer
Description

CytomX's Probody platform uses masking technology to render antibody therapeutics inert until activated in the tumor microenvironment — the same underlying conditional-activation thesis Cugene applies with VitoKine, applied to bispecific antibodies and cytokines.

TypeDirect peer
Description

Xilio develops tumor-activated immunotherapies, including masked IL-2 and IL-12 molecules (XTX101, XTX301), using a masking domain to limit systemic activity — closely paralleling Cugene's VitoKine platform and tumor-selective cytokine thesis.

TypeDirect peer
Description

Werewolf's PREDATOR platform engineers tumor-conditional IL-2 and IL-12 cytokines designed to be inert systemically and activated in the tumor microenvironment — conceptually analogous to Cugene's VitoKine masking approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cugene

Clinical-stage Biopharmaceuticals (Precision Immunotherapy)cugene.com

Cugene is a Boston-based clinical-stage biotechnology company developing precision immunotherapies — including Treg-selective IL-2 and TIL-targeting bispecifics — for cancer and autoimmune diseases, with CUG252 in Phase 1b trials and a worldwide license option held by AbbVie.

What Cugene does

Cugene, Inc. is a Boston-based clinical-stage biotechnology company founded in 2016, headquartered at 130 Turner Street, Suite 702, Waltham, MA. The company develops precision immunotherapies for cancer and autoimmune diseases using a biologics-based platform that combines engineered cytokines, bispecific antibodies, and a proprietary masking technology for tissue- or cell-selective targeting.

Cugene's pipeline is anchored by three technology platforms. CUG252 is a precision-engineered Treg-selective, long-acting IL-2 mutein designed to restore regulatory T cell functionality and suppress autoantibody production in autoimmune and inflammatory diseases, with an ongoing Phase 1b trial in Systemic Lupus Erythematosus (SLE) following FDA-cleared Phase 1a in healthy volunteers. In oncology, TILKine™ and VitoKine™ are TIL-targeting bispecific technologies engineered to selectively engage tumor-infiltrating lymphocytes, simultaneously blocking immune checkpoints and activating effector T cells through cis-signaling, with VitoKine additionally differentiated by a proprietary masking domain enabling tumor-specific activation. VitoKine-2 is a next-generation tumor-activable IL-2 therapeutic designed for monthly high-dose administration with an enlarged therapeutic window.

The business model is anchored on licensing and collaboration. In May 2022, Cugene entered into an exclusive worldwide license option agreement with AbbVie for CUG252 and other novel IL-2 muteins for autoimmune and inflammatory diseases, positioning the company to capture milestone and royalty economics while a major pharmaceutical partner handles global development and commercialization. The company is pre-revenue, with no disclosed product sales; revenue, if any, would flow from licensing milestones. The company markets through scientific conference presentations, peer-reviewed publications, and partnership announcements targeting investors and pharmaceutical partners rather than direct clinical end-users.

Cugene firmographics

Firmographics
Name
Cugene
Legal name
Cugene, Inc.
Website
https://cugene.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Cugene is a Boston-based clinical-stage biotechnology company developing precision immunotherapies — including Treg-selective IL-2 and TIL-targeting bispecifics — for cancer and autoimmune diseases, with CUG252 in Phase 1b trials and a worldwide license option held by AbbVie.
Ownership category
akta.pro rank

Cugene industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals (Precision Immunotherapy)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Clinical-stage biotechnology
  • Precision immunotherapy development
  • Autoimmune disease therapeutics
  • Oncology biologics
  • Engineered cytokine therapy

Where Cugene is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cugene business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Collaboration Agreements: Pre-revenue clinical stage company generating income through exclusive licensing agreements with pharmaceutical partners. AbbVie collaboration provides potential milestone and royalty payments for CUG252 and other IL-2 muteins.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Cugene product offering

Product offering

Core offering

Cugene is a Boston-based clinical-stage biotechnology company developing a pipeline of precision immunotherapies for cancer and autoimmune diseases. Its portfolio centers on biologics-based therapeutics including CUG252 (a Treg-selective long-acting IL-2 mutein for autoimmune/inflammatory diseases), TILKine and VitoKine (TIL-targeting bispecific technologies for solid tumors), and VitoKine-2 (an advanced tumor-activable IL-2). These candidates are integrated with a proprietary masking technology that enables tissue- or cell-selective targeting to minimize systemic toxicity.

Product overview

Cugene is a clinical-stage biotechnology company developing a pipeline of precision immunotherapies for cancer and autoimmune diseases. The company's product portfolio centers on its technology platform utilizing biologics-based therapeutics, including: CUG252 (a Treg-selective long-acting IL-2 for autoimmune diseases), TILKine™ and VitoKine™ (bispecific TIL-targeting technologies for oncology), and VitoKine-2 (an advanced tumor-activable IL-2 therapeutic). These products are integrated with proprietary masking technology and precision immuno-engineering to achieve tissue or cell-selective targeting with reduced systemic toxicity.

Differentiator

Problem solved

Functional benefit

Products and services

  • CUG252 A precision engineered Treg-selective, long-acting IL-2 mutein that abolishes binding to effector cells and retains full agonist activity on IL-2α. It restores full Treg functionality, suppresses autoantibody production, and restores immune homeostasis for treating autoimmune and inflammatory diseases including Systemic Lupus Erythematosus (SLE).
  • TILKine A TIL-targeting bispecific technology engineered to selectively engage tumor-reactive tumor-infiltrating lymphocytes (TILs) in the tumor environment. Through cis-signaling, it simultaneously blocks a key immune checkpoint and activates effector T cells, driving a potent and localized anti-tumor response. Aiming for first-line monotherapy for solid tumors.
  • VitoKine A TIL-targeting bispecific technology uniquely differentiated by a proprietary masking domain that enables tumor-specific TIL activation, minimizing systemic immune activation. Together with TILKine, these technologies reinvigorate exhausted T cells and expand tumor-killing effector T cells for precise and profound tumor eradication.
  • VitoKine-2 A precision-engineered tumor-activable IL-2 therapeutic designed to target tumor-infiltrating lymphocytes (TIL) in the tumor microenvironment. Uses unique masking technology to remain inert until activated, minimizing peripheral T cell activation and reducing systemic toxicities. Designed for monthly high-dose administration with an enlarged therapeutic window for both IO-responsive and unresponsive patients.

Quantifiable outcome

  • Complete tumor regressions observed in multiple cold and hot mouse models with efficacy superior to ICIs
  • +2 more outcomes

Companies that use Cugene

Customer profile

Segments2 records

Ideal customer profiles1 record

Cugene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cugene partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AbbViecoreStrategic or Co-development Partner · 16 May 2022AbbVie and Cugene entered into an exclusive worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well as other novel IL-2 muteins for the potential treatment of autoimmune and inflammatory diseases. This collaboration positions Cugene's pipeline for global development and potential commercialization through a major pharmaceutical partner.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Cugene competitors and assessment

Company assessment

Broad incumbents

  • Roche: Roche has multiple engineered IL-2 and IL-15 programs (including collaborations with Squarex and others) targeting Treg expansion for autoimmune disease, and is the dominant broad incumbent in oncology biologics — a relevant comparable for both halves of Cugene's pipeline.
  • Sanofi: Sanofi is a global immunology leader (Dupixent franchise) actively pursuing Treg-focused and engineered cytokine programs for autoimmune indications, and a major oncology biologics player — overlapping with Cugene on both autoimmune and oncology axes.
  • Eli Lilly: Lilly acquired Dice Therapeutics and is partnered with Nektar on rezpegaldesleukin (Treg-selective IL-2), placing it as a large-cap incumbent competitor in the same autoimmune IL-2 space as CUG252, with materially greater development and commercial resources.

Direct peers

  • Nektar Therapeutics: Nektar developed NKTR-358 (now rezpegaldesleukin, partnered with Eli Lilly), a Treg-selective IL-2 for autoimmune diseases — directly comparable to Cugene's CUG252 in mechanism, target selectivity approach, and indication strategy.
  • AnaptysBio: AnaptysBio is a clinical-stage biotech with proprietary antibody discovery and engineering platforms producing both wholly-owned and partnered antibodies for inflammation and immuno-oncology — comparable to Cugene in its biologics-platform-plus-pipeline model and therapeutic area focus.
  • Compass Therapeutics: Compass develops bispecific antibodies for oncology, with candidates designed to engage tumor-reactive immune cells — directly comparable to Cugene's TILKine/VitoKine bispecific strategy targeting tumor-infiltrating lymphocytes.
  • CytomX Therapeutics: CytomX's Probody platform uses masking technology to render antibody therapeutics inert until activated in the tumor microenvironment — the same underlying conditional-activation thesis Cugene applies with VitoKine, applied to bispecific antibodies and cytokines.
  • Xilio Therapeutics: Xilio develops tumor-activated immunotherapies, including masked IL-2 and IL-12 molecules (XTX101, XTX301), using a masking domain to limit systemic activity — closely paralleling Cugene's VitoKine platform and tumor-selective cytokine thesis.
  • Werewolf Therapeutics: Werewolf's PREDATOR platform engineers tumor-conditional IL-2 and IL-12 cytokines designed to be inert systemically and activated in the tumor microenvironment — conceptually analogous to Cugene's VitoKine masking approach.

Others

  • AbbVie: AbbVie is Cugene's exclusive worldwide license option partner for CUG252 and other IL-2 muteins — a large-cap pharma incumbent in immunology and oncology and a critical strategic counterparty rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Cugene social profiles

Digital presence

Cugene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cugene leadership team

Management profile

Number of profiles

Profiles1 record

Cugene funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cugene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cugene

What does Cugene do?

Cugene is a Boston-based clinical-stage biotechnology company developing a pipeline of precision immunotherapies for cancer and autoimmune diseases. Its portfolio centers on biologics-based therapeutics including CUG252 (a Treg-selective long-acting IL-2 mutein for autoimmune/inflammatory diseases), TILKine and VitoKine (TIL-targeting bispecific technologies for solid tumors), and VitoKine-2 (an advanced tumor-activable IL-2). These candidates are integrated with a proprietary masking technology that enables tissue- or cell-selective targeting to minimize systemic toxicity.

Is Cugene a public or private company?

Cugene is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cugene founded?

Cugene was founded in 2016. It employs 11 to 50 people.

Where is Cugene based?

Cugene is headquartered in Waltham, United States, in the North America region.

How does Cugene make money?

One revenue line is on record: licensing and Collaboration Agreements.

Who are Cugene's main competitors?

Broad incumbents on record are Roche, Sanofi and Eli Lilly. Direct peers are Nektar Therapeutics, AnaptysBio, Compass Therapeutics, CytomX Therapeutics, Xilio Therapeutics and Werewolf Therapeutics. AbbVie is listed as an others.

Does Cugene have an API?

No public API is recorded for Cugene.

What industry is Cugene in?

Cugene's product category is Clinical-stage Biopharmaceuticals (Precision Immunotherapy). Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAbbVie e a biotech Cugene Anunciam Parceria para Pesquisa em Doenças AutoimunesAbbVie and Cugene Inc. announced a worldwide exclusive licensing agreement for CUG252, a selective IL-2 mutein targeting regulatory T cells for treating autoimmune and inflammatory diseases. Under the terms, Cugene will receive a $48.5 million upfront payment and may receive additional regulatory, commercialization, and sales milestones plus tiered royalties, while conducting Phase 1a and 1b studies before AbbVie assumes full development, manufacturing, and commercialization responsibilities. The deal underscores AbbVie's continued investment in immunology pipeline assets and provides Cugene with global resources to advance its precision engineering platform.BioSpaceAbbVie, AstraZeneca See Value in what Cugene, Proteros Have to OfferCugene and AbbVie announced a collaboration to develop autoimmune and cancer treatments, with AbbVie paying $48.5 million upfront for CUG252. Proteros and AstraZeneca expanded their epigenetic cancer drug partnership, adding undisclosed research funding and milestones up to $75 million.PR NewswireAbbVie and Cugene Announce Collaboration in Autoimmune DiseasesAbbVie and Cugene announced an exclusive worldwide license option for CUG252, a Treg-selective IL-2 mutein, with Cugene receiving a $48.5 million upfront payment. Cugene will conduct a Phase 1b study in autoimmune patients during the option period, and AbbVie will lead all future development and commercialization upon exercise.